secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001564590-22-000853
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint appoints Michael C. Pine as Chief Corporate Development and Strategy Officer
--------------------------------------------------------------------------------

- Appointed Michael C. Pine as Chief Corporate Development and Strategy Officer, effective January 10, 2022.
- Annual base salary of $420,000; sign-on bonus of $108,000 payable in two equal tranches.
- Granted options to purchase 100,000 shares at $12.62/share, vesting 25% on first anniversary then monthly through fourth year.
- Mr. Pine brings over 20 years of pharma experience, most recently SVP at Medexus Pharmaceuticals.
- Inducement award under Nasdaq Listing Rule 5635(c)(4); subject to forfeiture provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/0001564590-22-000853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/eypt-8k_20220110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-000853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer